Evidence map›Paper›PMID 36842771›Full record

Trial reportMetabolism: clinical and experimental2023

Blood immune cells from people with HIV on antiviral regimens that contain tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have differential metabolic signatures.

Eleni Ritou, Sandro Satta, Anton Petcherski, Maria Daskou, Madhav Sharma, Hariclea Vasilopoulos, Eisuke Murakami, Orian S Shirihai, Theodoros Kelesidis

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Metabolism: clinical and experimental, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Eleni RitouDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Sandro SattaDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Anton PetcherskiDepartment of Medicine, Division of Endocrinology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Maria DaskouDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Madhav SharmaDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Hariclea VasilopoulosDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Eisuke MurakamiGilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, USA.
Orian S ShirihaiDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Theodoros KelesidisDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: tkelesidis@mednet.ucla.edu.
University of California, Los Angeles · USGilead Sciences (United States) · US

Funding

Targeting early instigators of vascular inflammation to prevent and/or delay vascular aging in chronic treated HIVR01AG059502 · NIA · UT SOUTHWESTERN MEDICAL CENTER · PI KELESIDIS, THEODOROS · 2018 to 2022
$2.0M
Selective Tuning of Stem Cell Extracellular Vesicles as a Novel Therapy for Age-related TendinopathyR43AG059501 · NIA · ZEN-BIO, INC. · PI BUEHRER, BENJAMIN M, LUDLOW, JOHN WILLIAM · 2018 to 2018
$222k
Elucidating the impact of molecular signatures of immune senescence on aging in chronic treated HIVR03AG059462 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KELESIDIS, THEODOROS · 2018 to 2019
$156k
NIA NIH HHS R01 AG059502NIA NIH HHS R03 AG059462NIA NIH HHS R43 AG059501
6 · The paper itself

Abstract

backgroundMitochondria regulate immune and organ function. It is unknown whether higher intracellular drug levels observed in peripheral blood mononuclear cells (PBMCs) treated with tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) may alter mitochondrial function and energy production in immune cells in HIV

methodsCellular bioenergetics were determined in PBMCs from HIV-1

resultsPBMCs from HIV-1

conclusionsCompared to TDF, TAF may alter bioenergetics in immune cells from PWH in vitro and in vivo. The clinical significance in terms of the differential impact caused by TAF versus TDF on mitochondrial function and energy production in immune cells, a regulator of immune function, requires further studied in HIV, preexposure prophylaxis and hepatitis B.

Indexed as

Anti-HIV AgentsHIV InfectionsAdenineAlanineHumansLeukocytes, MononuclearTenofovirAdenineAlanineAnti-HIV AgentsTenofovirAntiviralsHIVImmune cellsMetabolismMitochondriaTenofovir alafenamide (TAF)Tenofovir disoproxil fumarate (TDF)

Identifiers

PMID36842771
PMCPMC10932727
OpenAlexW4316011090

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.